Standard Biotools (LAB) Cash & Equivalents (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cash & Equivalents data on file, last reported at $265.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 73.17% year-over-year to $265.8 million in Q1 2026; TTM through Mar 2026 was $265.8 million, a 73.17% increase from a year earlier, with the FY2025 full-year figure at $120.9 million, down 28.41% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $265.8 million, up from $120.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LAB reached as high as $288.3 million in Q1 2024 and fell as low as $31.0 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $141.7 million across 5 years, with a median of $129.4 million in 2025.
• Across the five-year window, Cash & Equivalents surged 7319.0% in 2022 and tumbled 46.78% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $82.3 million in 2022, then slumped by 36.23% to $52.5 million in 2023, then surged by 221.56% to $168.8 million in 2024, then dropped by 28.41% to $120.9 million in 2025, then jumped by 119.9% to $265.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $265.8 million in Q1 2026, $120.9 million in Q4 2025, and $129.4 million in Q3 2025.